Update on stents: Recent studies on the TAXUS® stent system in small vessels

Shuzou Tanimoto
Joost Daemen
Patrick W Serruys
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands

Abstract: Small vessel size (<3 mm) has been identified as an independent predictive factor of restenosis after percutaneous coronary intervention when using bare metal stents (BMS). It remains controversial whether BMS placement in small vessels has an advantage over balloon angioplasty in terms of angiographic and clinical outcomes. The advent of drug eluting stents (DES), either paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES), has strongly impacted interventional cardiology by significantly reducing restenosis and the need for repeat revascularization. Therefore, it was also expected that DES could substantially reduce restenosis in smaller vessels. However, even in the DES era, small vessel size remains an independent predictor of angiographic and clinical restenosis. To date, only a few studies systematically investigate the clinical effect of DES placement in small vessels. In addition, some potential issues with the use of DES have been raised, such as late stent thrombosis and late restenosis. In order to (i) establish the superiority of DES over BMS; (ii) verify the efficacy and safety of DES; and (iii) critically assess the superiority of one DES over the other in patients with small coronary arteries, further multicenter, randomized clinical trials with larger sample size are warranted.

Keywords: paclitaxel, stent, coronary artery disease, restenosis

Introduction

Percutaneous coronary intervention (PCI) is a major treatment strategy for patients with coronary artery disease (CAD), and currently coronary stents are widely used in the world (Brophy et al 2003). As compared to balloon angioplasty, bare metal stents (BMS) prevent both early elastic recoil and late vascular remodeling. These abilities of BMS reduce coronary restenosis and significantly improve the angiographic and clinical outcomes in vessels with a reference vessel diameter (RVD) typically more than 3 mm as assessed by quantitative coronary angiography (QCA) (Serruys et al 1994; Fischman et al 1994; Macaya et al 1996; Betriu 1999; Kiemeneij 2001). On the contrary, in terms of stent implantation in vessels with a RVD = 3 mm, several randomized trials have failed to show an advantage of BMS over balloon angioplasty (Kastrati et al 2000; Park et al 2000; Koning et al 2001; Moer et al 2001). A recent meta-analysis of small vessel BMS stenting reported that rates of restenosis, repeat revascularization and major adverse cardiovascular events (MACE; defined as death, myocardial infarction (MI), and repeat revascularization) were 27.8%, 14.9% and 17.6%, respectively (Agostini et al 2005). The high observed restenosis rate (27.8%) may be attributed to a comparable absolute late lumen loss after stenting in both small and large vessels: a similar small volume of neointimal hyperplasia would induce a diameter stenosis = 50% in small vessels more easily compared to large vessels by virtue of their smaller RVD (Akiyama et al 1998). The higher angiographic restenosis rate may translate into high repeat revascularization and MACE rates in the...
Paclitaxel and TAXUS® stent system

Paclitaxel is an anti-tumor agent used to treat several kinds of solid tumors, most commonly tumors of the breast and ovary. This drug interferes with microtubule organization by interrupting mitosis (M phase) and extracellular secretion. Microtubular dynamics regulate many of the inflammatory and profibrotic steps of the restenosis cascade. Paclitaxel interrupts this cascade at multiple levels and inhibits cell proliferation and migration (Axel et al 1997; Hui et al 1998; Giannakakou et al 2001).

Use of the TAXUS® stent system in patients with CAD has been fully investigated in the TAXUS trials (see Table 1). Results from a total of 6 TAXUS trials have been reported to date (Grube et al 2003; Colombo et al 2003; Tanabe et al 2003; Stone et al 2004a; Stone et al 2005, Dawkins et al 2005). Follow-up of patients in 4 TAXUS trials (TAXUS II, IV, V, and VI) are still ongoing as of the date of this review. Several versions of the TAXUS stent technology using different platform types (NIRx, EXPRESS, EXPRESS²) and drug release kinetics (slow-release and moderate-release) but similar polymers, stent materials and drug concentrations (1.0 µg/mm² of paclitaxel), were used among these 6 trials (see also Table 1).

The TAXUS NIRx stent was a slotted-tube stainless steel stent coated with paclitaxel incorporated into a slow-release (SR) or a moderate-release (MR) copolymer carrier system with biphasic drug release. The initial release is over the first 48 hours followed by SR over the next 10 days. Release kinetics of the TAXUS NIRx MR stent in vivo has been shown to be faster than that of the TAXUS NIRx SR stent, resulting in a 3-fold higher in vivo drug release at 10 days. The TAXUS EXPRESS stent consists of a balloon-expandable EXPRESS stent with TRANSLUTE™ polymer-coating containing paclitaxel. The TAXUS EXPRESS² stent is composed of a balloon-expandable EXPRESS² stent with a triblock copolymer coating with paclitaxel. This coating serves as a carrier to provide uniform and controlled biphasic release of the drug into the vessel wall. SR and MR formulations of the polymer are available in the TAXUS EXPRESS² stent. The MR formulation also results in approximately 3-fold higher drug release than the SR polymer. The SR polymer formulation of the TAXUS EXPRESS² stent is commercially available now.

PES versus BMS in small vessels

So far, no dedicated, prospective multicenter, randomized clinical study comparing the PES to BMS in patients with small vessel disease has been conducted. However, the
Table 1  An overview of the TAXUS trials

|                | TAXUS I            | TAXUS II           | TAXUS III          |
|----------------|--------------------|--------------------|--------------------|
|                | (Grube et al 2003) | (Colombo et al 2003) | (Tanabe et al 2003) |
| Published year | 2003               | 2003               | 2003               |
| Trial design   | Randomized         | Randomized         | Single arm         |
| Used device    | TAXUS NIRx         | TAXUS NIRx         | TAXUS NIRx         |
| Release kinetics | SR                | SR and MR         | SR                |
| Patient number | TAXUS 31 Control 30 | TAXUS SR 131, SR control 136 | TAXUS 28         |
| Lesion morphology | Single de novo or restenotic lesion in a native coronary artery | Single de novo lesion in a native coronary artery | In-stent restenosis in a native coronary artery with evidence of ischemia |
| Lesion length  | = 12 mm            | = 12 mm            | = 30 mm            |
| Vessel diameter | 3.0 to 3.5 mm      | 3.0 to 3.5 mm      | 3.0 to 3.5 mm      |
| Primary endpoint | MACE at 30 days    | Mean % stent volume obstructed by neointimal proliferation measured by IVUS at 6 months | N/A               |

TAXUS IV trial

In the TAXUS IV trial (Stone et al 2004a, 2004b), various types of subgroup analyses were performed. With regard to vessel size, enrolled patients were divided into the following 3 groups per RVD; = 2.5 mm, > 2.5 mm to < 3.0 mm and = 3.0 mm. In the smallest RVD group (= 2.5 mm, n = 176), the 9-month angiographic restenosis rate in the PES group was significantly lower than in the BMS group (PES, 10.2% versus BMS, 38.5%; p < 0.001). In addition, 12-month target lesion revascularization (TLR) rate was significantly lower in the PES group (5.6%) as compared to the BMS group (20.6%, p < 0.0001). Moreover, in multivariate analysis, the RVD was not related with 12-month TLR rate in the PES group, while it was an independent predictor of 12-month TLR rate in the BMS group. No other angiographic parameters and clinical outcomes in this subgroup analysis were reported in this trial.

TAXUS V trial

In the TAXUS V trial (Stone 2005), subgroups of patients with complex lesions, requiring 2.25 mm or 4.0 mm long stents and multiple stents (>1 stent), were investigated. In the patient group treated with the 2.25 mm stent, which consisted of 17.6% of total enrolled population, the mean RVD was 2.08 mm. Both treatment groups (PES and BMS) had similar acute clinical outcomes. At the 9-month follow-up, the restenosis rate as well as repeat revascularization rate was significantly lower in the PES group than in the BMS group (31.2% and 10.4% [PES] versus 49.4% and 21.5% [BMS]; p = 0.01 and 0.03, respectively), although both parameters in the PES group were still high. In this underpowered posthoc analysis, numerical differences in the 9-month MACE rate between both treatment groups did not reach statistical significance (18.9% [PES] versus 26.9% [BMS]; p = 0.23).
Of note, the rate of periprocedural MIs in the PES arm was numerically higher than in the BMS arm without any statistical significance (5.7% versus 2.2%, \( p = 0.27 \)). Designed as a trial assessing outcomes in more complex lesions, most of the affected patients were characterized by an overlap of multiple complexities such as treatment of longer lesions in smaller vessels often with multiple overlapping stents.

**TAXUS VI trial**

In the TAXUS VI trial (Dawkins 2005), angiographic and clinical outcomes were followed up to 9 months. Some subgroup analyses were performed per classic risk factors for restenosis, including clinical outcomes in patients with small vessels (RVD <2.5 mm). In this subgroup, in-stent late lumen loss was considerably smaller in the PES group than in the BMS group (PES, 0.23 ± 0.45 mm versus BMS, 0.95 ± 0.52 mm; \( p < 0.0001 \)), explaining the significantly lower angiographic restenosis observed in the PES group (7.3% [PES] versus 40.4% [BMS]; \( p < 0.0001 \)). The incidence of TLR was also significantly lower in the PES group (5.0% [PES] versus 29.7% [BMS]; \( p = 0.0003 \)).

Taking these results into the consideration, PES seems to confer clinical benefit in patients with small vessels compared to BMS. As shown in angiographic assessments, PES markedly inhibit in-stent and in-segment (including implanted stent and 5 mm distal and proximal to the stent) neointimal hyperplasia, contributing to the significantly lower TLR rate observed in these patients (see Table 2). To date, however, PES implantation in small vessels has not been studied prospectively in a dedicated study. Only subgroup analysis data exist and the number of study patients is very small. Future multicenter randomized trials with large sample size, which focus on patients treated with PES for small vessel CAD, are required to better understand whether PES is more effective in patients with small vessels than BMS.

**SES versus BMS in small vessels**

SES is another commercially available DES promising improved clinical and angiographic results in patients with small vessel disease as compared to BMS. In contrast to paclitaxel, only a single stent type coated with one specific dose formulation for controlled release of sirolimus has been

---

### Table 2 Clinical and angiographic results in patients with small vessel disease in the TAXUS trials

|                      | TAXUS IV subanalysis | TAXUS V subanalysis | TAXUS VI subanalysis |
|----------------------|----------------------|----------------------|----------------------|
|                      | RVD <2.5 mm          | 2.25 mm stent implantation | RVD <2.5 mm          |
|                      | (Stone et al 2004a, 2004b) | (Stone et al 2005) | (Dawkins et al 2005) |
| Clinical outcomes    |                      |                      |                      |
| Acute phase          |                      |                      |                      |
| Death                | 30 days              |                      |                      |
| MI                   | 0.9%                 | 0.9%                 | 0.9%                 |
| TLR                  | 0.9%                 | 1.9%                 | 1.9%                 |
| TVR                  | 1.9%                 | 2.1%                 | 2.1%                 |
| MACE                 | 2.2%                 | 5.6%                 | 5.6%                 |
| Stent thrombosis     | 0.9%                 | 1.9%                 | 1.9%                 |
| Follow up            | 12 months            | 9 months             | 9 months             |
| Death                | 1.9%                 | 1.9%                 | 1.9%                 |
| MI                   | 5.7%                 | 5.7%                 | 5.7%                 |
| TLR                  | 5.6%                 | 20.6%                | 10.4%                |
| TVR                  | 16.0%                | 24.7%                | 24.7%                |
| MACE                 | 18.9%                | 26.9%                | 26.9%                |
| Stent thrombosis     | 1.0%                 | 1.1%                 | 1.0%                 |
| Baseline QCA         |                      |                      |                      |
| RVD                  | 2.07 ± 0.31          | 2.10 ± 0.33          | 2.10 ± 0.33          |
| Lesion length        | 16.6 ± 9.7           | 16.4 ± 9.2           | 16.4 ± 9.2           |
| Follow-up QCA        | 9 months             | 9 months             | 9 months             |
| Late Loss (instent)  | 0.49 ± 0.61          | 0.90 ± 0.63          | <0.001               |
| Late Loss (segment)  | 0.36 ± 0.53          | 0.61 ± 0.59          | 0.004                |
| Restenosis (instent) | 24.7%                | 44.7%                | 44.7%                |
| Restenosis (segment) | 31.2%                | 49.4%                | 49.4%                |

**Notes:**
- BMS, bare metal stent; MACE, major adverse cardiac events; MI, myocardial infarction; PES, paclitaxel-eluting stent; QCA, quantitative coronary angiography; RVD, reference vessel diameter; TLR, target lesion revascularization; TVR, target vessel revascularization.
- \( <0.001 \) indicates statistical significance at the 0.001 level.
- All values are expressed as mean ± standard deviation.
investigated over the last several years: the SES consists of the Bx Velocity stent loaded with 1.4 ug/mm² sirolimus. Sirolimus is a macrolide with immunosuppressive, antiproliferative and antifungal properties. Different from the mechanism of paclitaxel, sirolimus prevents progression from the G1 phase (cell growth) to the S phase (DNA replication), resulting in inhibition of the growth of vascular smooth muscle cells, which is a major process of in-stent restenosis.

The SIRIUS trial showed that SES had a significant lower 1-year TLR rate than BMS in patients with RVD ≤2.75 mm (6.6% [SES] versus 22.3% [BMS]; p < 0.0001) (Holmes et al 2004). In an angiographic substudy of the SIRIUS trial (Popma et al), patients were categorized into tertiles according to RVD and angiographic outcomes between SES and BMS were assessed. The smallest tertile had mean RVD of 2.32 mm in the SES group and 2.31 mm in the BMS group (p = 0.683). Angiographic restenosis rate in the SES group was significantly lower than in the BMS group (17.6% vs 42.7%, p < 0.001). The SES-SMART trial (Ardisso et al 2004), which enrolled patients with small vessels (mean RVD 2.2mm), indicated that the incidence of TLR and MACE in the SES arm was 7.0% and 9.3% versus 21.1% and 31.3% in the BMS arm (p = 0.002 and p < 0.001, respectively). In addition, angiographic restenosis rate in the SES arm was also significantly lower compared to the BMS arm (9.8% vs 53.1 %, p < 0.001).

These results indicated that SES is no less effective than PES in patients with small vessel CAD. However, which DES is superior to the other in small vessel stenting still remains controversial.

**PES versus SES in small vessels**

Several recent trials (de Lezo et al 2005; Kastrati et al 2005a; Dibra et al 2005; Windecker et al 2005; Goy et al 2005; Morice et al 2006) and a meta-analysis (Kastrati et al 2005b) have compared PES with SES. While suggesting advantages of SES in reducing neointimal hyperplasia, many of the comparative trials have been limited by inadequate sample size, execution in single center, and use of institutional rather than independent core labs and event committees limiting the acceptability of these datasets for establishment of formal treatment guidelines. Indeed, when these comparative trials are scored by Silver score (Silber 2005) (see Table 3), which rate the level of evidence provided by the various DES trials (range from 0 to 10) and intend to help physicians evaluate the strength of evidence, calculated scores are relatively low (high scores can be considered strong evidence): CORPAL study (de Lezo et al 2005) is 1, ISAR-DESIRE (Kastrati et al 2005a) 4, ISAR-DIABETES(Dibra et al 2005) 4, SIR-TAX (Windecker et al 2005) 6, TAXi (Goy et al 2005) 5 and REALITY (Morice et al 2006) 4. In addition, there is limited information on the relative efficacy and safety of PES compared to SES in patients with small vessel disease. Only 3 trials were reported: 1 randomized trial and 2 non-randomized trials (see Table 4). We describe these 3 trials in the section below.

### Table 3 Silver score system

| Evaluation Parameter                                                                 | Possible points |
|-------------------------------------------------------------------------------------|-----------------|
| Clinical Primary Endpoint (TLR, TVR, TVF, MACE)                                      | Yes = 3         |
| Double-Blind (including physicians)                                                 | No = 0          |
| Evaluation Interval of Primary Endpoint ≥6 Months                                     | Yes = 1         |
| Multi-Center (at least 3 centers)                                                   | No = 0          |
| Clinical Events Committee/Data Safety Monitoring Board Independent and External from Steering Committee | Yes = 1         |
| Primary Endpoint Reached                                                             | No = 0          |
| Power of ≥80% for Primary Endpoint Achieved                                          | Yes = 1         |
| Follow-up Percentage ≥80% for Angiographic Primary Endpoint or Follow-up Percentage of ≥95% for Clinical Primary Endpoint | No = 0          |

| Maximum Silber Score | 10 |
| Minimum Silber Score | 0  |

TLR, target lesion revascularization; TVF, target vessel failure; TVR, target vessel revascularization; MACE, major adverse cardiac events.
The ISAR-SMART 3 trial was a first head-to-head comparative (PES vs SES) randomized trial for patients with small vessel disease (mean RVD was about 2.4 mm) (Mehilli et al 2006). Angiographic and clinical outcomes were followed up to 8 months. SES was more effective in reducing restenosis and TLR than PES (11.4 and 6.6% in the SES group vs 19.0 and 14.7% in the PES group, p = 0.047 and 0.008, respectively). These results indicated that PES induced a greater late lumen loss and were less effective in reducing restenosis in small coronary vessels as compared to SES. Consequently, SES was associated with a lower incidence of angiographic restenosis as well as a reduced need of repeat revascularization.

There were 2 additional non-randomized trials comparing the efficacy between PES and SES in patients with small vessel disease. One was a study of Park et al, which was a retrospective study including 197 patients with a mean RVD of nearly 2.45 mm (Park et al 2006). Angiographic restenosis rate at 6 months and TLR rate at 9 months were 6.7 and 3.3% in the SES group, while 27.7 and 14.4% in the PES group (p < 0.01 and < 0.01, respectively).

**Table 4 Clinical and angiographic results of the studies comparing PES to SES implantation in patients with small vessel disease**

|                      | ISAR-SMART 3 (Mehilli et al 2006) | Park et al (Park et al 2006) | RESEARCH and T-SEARCH subanalysis (Rodriguez-Granillo et al 2005; Tanimoto et al 2006) |
|----------------------|----------------------------------|-----------------------------|---------------------------------------------------------------------------------------|
|                      | SES | PES | p value | SES | PES | p value | SES | PES | p value |
| Patient number       | n = 180 | n = 180 |          | n = 121 | n = 76 |          | n = 107 | n = 92 |          |
| Trial design         | Randomized trial | Non-randomized trial |          | Non-randomized trial |          |          |          |          |          |
| **Clinical outcomes**|      |      |          |      |      |          |      |      |          |
| **Acute phase**      |      |      |          |      |      |          |      |      |          |
| Death                |      |      |          |      |      |          |      |      |          |
| MI                   | 3.9% | 3.3% | 0.78 | 12.4% | 13.2% | 0.54 | 2.8% | 6.7% | 0.31 |
| TLR                  | 0%   | 0%   | 0.32 | 0%   | 0%   | 1      | 2.8% | 5.6% | 0.47 |
| TVR                  |      |      |          |      |      |          |      |      |          |
| MACE                 |      |      |          |      |      |          |      |      |          |
| Stent thrombosis     | 0%   | 0%   | >0.99 | 0%   | 0%   | 1      | 0%   | 2.2% | 0.21 |
| **Follow up**        |      |      |          |      |      |          |      |      |          |
| 12 months            |      |      |          |      |      |          |      |      |          |
| Death                | 1.7% | 2.2% | >0.99 | 0%   | 0%   | 1      | 0.9% | 4.3% | 0.18 |
| MI                   | 3.9% | 3.3% | 0.78 | 12.4% | 13.2% | 0.54 | 2.8% | 7.8% | 0.19 |
| TLR                  | 6.6% | 14.7% | 0.008 | 3.3% | 14.4% | <0.01 | 6.5% | 11.1% | 0.31 |
| TVR                  |      |      |          |      |      |          |      |      |          |
| MACE                 |      |      |          |      |      |          |      |      |          |
| Stent thrombosis     | 0%   | 0%   |          | 0%   | 0%   |          | 0%   | 2.2% | 0.21 |
| **Baseline QCA**     |      |      |          |      |      |          |      |      |          |
| RVD                  | 2.44 ± 0.34 | 2.40 ± 0.38 | 0.34 | 2.47 ± 0.21 | 2.44 ± 0.25 | 0.19 | 1.86 ± 0.37 | 1.95 ± 0.38 | 0.15 |
| MLD                  | 0.99 ± 0.40 | 1.03 ± 0.39 | 0.33 | 0.86 ± 0.33 | 0.81 ± 0.42 | 0.31 | 0.47 ± 0.38 | 0.57 ± 0.38 | 0.06 |
| DS                   | 59.4 ± 15.3 | 57.2 ± 14.4 | 0.15 | 65.4 ± 13.0 | 67.5 ± 16.0 | 0.22 | 74.8 ± 20.1 | 70.3 ± 19.3 | 0.10 |
| Lesion length        | 12.9 ± 8.0 | 11.7 ± 6.7 | 0.12 | 25.2 ± 14.7 | 27.1 ± 12.7 | 0.34 | 13.0 ± 8.5 | 16.4 ± 10.4 | 0.02 |
| **Post-PCI QCA**     |      |      |          |      |      |          |      |      |          |
| MLD (instant)        | 2.44 ± 0.36 | 2.44 ± 0.37 | 0.8 | 1.73 ± 0.31 | 1.82 ± 0.36 | 0.06 |          |          |      |
| MLD (segment)        | 2.04 ± 0.47 | 2.00 ± 0.47 | 0.41 | 2.52 ± 0.33 | 2.42 ± 0.35 | 0.45 | 12.3 ± 10.0 | 14.0 ± 9.8 | 0.19 |
| DS (instant)         | 5.6 ± 7.5 | 6.3 ± 7.7 | 0.36 |          |          |      |          |          |      |
| DS (segment)         | 16.7 ± 7.1 | 18.3 ± 7.2 | 0.05 | 3.7 ± 7.1 | 5.8 ± 8.3 | 0.06 |          |          |      |
| **Follow-up QCA**    |      |      |          |      |      |          |      |      |          |
| MLD (instant)        | 2.21 ± 0.66 | 1.88 ± 0.67 | <0.001 |          |          |      |          |          |      |
| MLD (segment)        | 1.91 ± 0.61 | 1.67 ± 0.63 | <0.001 | 2.32 ± 0.56 | 1.77 ± 0.77 | <0.01 |          |          |      |
| DS (instant)         | 17.2 ± 21.5 | 26.7 ± 21.8 | <0.001 |          |          |      |          |          |      |
| DS (segment)         | 28.4 ± 19.7 | 35.0 ± 20.6 | <0.002 | 5.38 ± 22.5 | 31.7 ± 34.9 | <0.01 |          |          |      |
| Late loss (instant)  | 0.25 ± 0.55 | 0.56 ± 0.59 | <0.001 |          |          |      |          |          |      |
| Late loss (segment)  | 0.13 ± 0.56 | 0.34 ± 0.57 | <0.001 | 0.29 ± 0.42 | 0.69 ± 0.62 | <0.01 |          |          |      |
| Restenosis (instant) | 8.0% | 14.9% | 0.04 |          |          |      |          |          |      |
| Restenosis (segment) | 11.4% | 19.0% | 0.047 | 6.7% | 27.7% | <0.01 |          |          |      |

DS, diameter stenosis; MACE, major adverse cardiac events; MI, myocardial infarction; MLD, minimal lumen diameter; PES, paclitaxel-eluting stent; QCA, quantitative coronary angiography; RVD, reference vessel diameter; SES, sirolimus-eluting stent; TLR, target lesion revascularization; TVR, target vessel revascularization.
Another was a substudy of the RESEARCH and T-SEARCH registries, which adopted a non-randomized design (Rodriguez-Granillo et al 2005, Tanimoto et al 2006). This substudy was the only 1 investigating long-term follow-up (up to 2 years) of patients treated with PES or SES in small coronary vessels. Patients treated with 2.25 mm diameter PES or SES were evaluated in terms of clinical outcomes without systematic angiographic follow-up and therefore evaluated only clinical benefit. The incidence of 1 year TLR and MACE systematic angiographic follow-up and therefore evaluated or SES were evaluated in terms of clinical outcomes without coronary vessels. Patients treated with 2.25 mm diameter PES up (up to 2 years) of patients treated with PES or SES in small vessels. This substudy was the only 1 investigating long-term follow-up T-SEARCH registries, which adopted a non-randomized design (Rodriguez-Granillo et al 2005, Tanimoto et al 2006). TLR at 2 years was observed more frequently in the PES group (12.2% vs 6.5% in the SES group, p = 0.22); only 1 patient in the PES arm underwent repeat revascularization in the second year. The 2-year MACE rate was significantly higher in the PES group than in the SES group (23.3% vs 10.3%, p = 0.02).

Considering these results, SES has been implied to offer slight advantages over PES in small vessel stenting regarding angiographic and sometimes even clinical outcomes. Nevertheless, the root cause for such differences between PES and SES remains unclear. The mechanical differences of both DES may affect angiographic restenosis as a study of Briguori et al which showed that strut thickness was an independent predictor of angiographic restenosis in small coronary arteries (RVD of 2.75 to 2.99 mm); thinner-strutted stents were associated with lower incidence of restenosis than thicker-strutted stents (Briguori et al 2002). But the strut thicknesses of PES and SES are very similar (0.132 mm and 0.140 mm, respectively) so that such a mechanical property does not influence the result of angiographic outcomes obtained by both DES implantations. Different mechanisms of inhibiting neointimal hyperplasia and drug-release kinetics between PES and SES presumably accounts for the observed difference in their performance.

At the moment, however, it is difficult to conclude that SES is superior to PES in small vessel stenting. It is underscored that to date only one randomized controlled trial (ISAR-SMART 3) was performed to compare differences between PES and SES in small vessel stenting. This randomized study was open-labeled trial and was conducted at only 2 investigative sites, therefore the Silver score is 3 out of 10. In addition, this study excluded patients with diabetes mellitus, which was a famous independent predictor leading to worse angiographic and clinical outcomes. Moreover, the number of enrolled patients in each study was too small and underpowered to definitely assess the effectiveness of both DES for small coronary artery lesions regarding with TLR, TVR or MACE. The other 2 trials comparing the efficacy of PES and SES in small vessels were non-randomized studies so that their strength of evidence were low. Inclusion and exclusion criteria of each study varied. It must be noted that larger, multicenter (at least ≥3), randomized, blinded trials, with a defined clinical endpoint in patients with small vessels are required to firmly determine a clinical advantage of one DES over the other. As of present, limited results from these 3 trials do not confirm a significant advantage of SES over PES in this patient population.

**Safety concern of small vessel DES stenting**

After DES were approved, these devices have been implanted in a large number of patients with CAD including several kinds of clinical and anatomic situations such as acute MI, bifurcation lesions and overlapping stent deployment. Their use seems to be feasible and safe. Recently, however, certain potential issues have been raised.

One of the issues is stent thrombosis. Although rare, some studies have cautioned that as compared to BMS, either PES or SES could increase the incidence of this complication, especially that of late stent thrombosis (occurring >30 days after stent placement) (McFadden et al 2004; Iakovou et al 2005; Ong et al 2005; Moreno et al 2005). Increased risk for thrombosis may be associated with the decreased endothelial function (Hofma et al 2006), and/or delayed vascular healing (Degertekin et al 2002; Guagliumi et al 2003; Joner et al 2006) induced with DES. In addition, hypersensitivity reactions to the polymer coating of the DES and the drug itself may also contribute to stent thrombosis (Virmani et al 2004; Nebecker et al 2006). Although BMS implantation in small vessels had been previously cited as a risk factor for stent thrombosis (Karrillon et al 1996; Mak et al 1996; Moussa 1997), improved techniques of optimal stent deployment and dual antiplatelet regimens appear to have largely resolved this problem so that the risk of stent thrombosis of BMS in small vessel stenting now seems to be similar to that in larger vessel stenting (Akiyama 1998; Lau et al 2000). But, DES implantation in small vessels may increase the risk of stent thrombosis because of their features as mentioned above. The incidence of stent thrombosis in small vessel DES stenting has not been shown to differ between PES and BMS or SES. In a subanalysis conducted in the TAXUS V clinical trial, both acute and late stent thrombosis rate were similar between PES and BMS (0.9% versus 1.1% and 1.0% versus 1.1%, p = 1.00 and 1.00, respectively) (Table 2).
the ISAR-SMART 3 trial and a study of Park et al, no acute stent thrombosis was reported in both the SES and PES arms, while there was no information about late stent thrombosis in either trial (see Table 4). In a subanalysis of the RESEARCH and T-SEARCH registries, 2.2% of patients had acute stent thromboses in the SES arm; no thrombosis was observed in the PES arm (see also Table 4). This observation was not significant (p = 0.21). No late stent thrombosis occurred in either arm. It should be mentioned that the definition of stent thrombosis varied (clinical or angiographic) and treated lesion type differed among clinical trials. In addition, though most trials reported their outcomes within 1 year, late stent thrombosis often occurred more than 1 year after DES placement. To better understand this adverse event, a much larger sample size and longer-term follow-up are warranted.

Delayed restenosis, which is also called a “late catch-up phenomenon”, is another issue after DES deployment. This event was first observed in the porcine model (Farb et al 2001; Carter et al 2004). Also in humans, continued neointimal growth during the follow-up period was noted in some trials in which serial intravascular ultrasound (IVUS) analyses were performed (Aoki et al 2005a; Aoki et al 2005b; Aoki et al 2005c). The precise reason for this phenomenon is still unclear. Delayed neointimal hyperplasia could lead to higher incidence rates of TLR and MACE observed during long-term follow-up. This is especially relevant with small vessel DES stenting, since even a small volume of neointimal tissue can affect the incidence of angiographic restenosis by virtue of the smaller RVD. With respect to small vessel stenting, few long-term follow-up data exist (Table 5). In a subanalysis of the SIRIUS 2-year outcomes (Weisz et al 2006), TLR rate in the second year was 1.7% in the SES group and 0.8% in the BMS group (p = 0.17). In a substudy of the RESEARCH and T-SEARCH registries, only 1 patient (1.1%) treated with PES presented with TLR in the second year (0% in the SES arm, p = 0.46). In these 2 studies, angiographic parameters were not reported, thus the increase of neointima was unknown during the second year. However, according to these results, it may be inferred that if late catch-up phenomenon occurred after small vessel DES stenting, its effect might be restrictive in this clinical setting. The efficacy of DES was ascertained up to 2-years even in treatment of small vessel CAD.

Table 5 Long-term clinical follow-up trials in small vessel DES stenting

|                    | SIRIUS subanalysis RVD < 2.75 mm (Weisz et al 2006) | RESEARCH and T-SEARCH subanalysis (Tanimoto et al 2006) |
|--------------------|-----------------------------------------------------|-----------------------------------------------------|
|                    | SES       | BMS       | p value | SES       | PES       | p value |
| Patient number     | n = 533   | n = 525   |         | n = 107   | n = 92    |         |
| Trial design       | Randomized trial | Non-randomized trial | | |
| 1-year follow up   |           |           |         |           |           |         |
| death              |           |           |         |           |           |         |
| MI                 |           |           |         |           |           |         |
| TLR                | 6.6%      | 22.3%     | <0.0001 |           |           |         |
| TVR                |           |           |         |           |           |         |
| MACE               |           |           |         |           |           |         |
| Stent thrombosis   |           |           |         |           |           |         |
| 2-year follow up   |           |           |         |           |           |         |
| death              |           |           |         |           |           |         |
| MI                 |           |           |         |           |           |         |
| TLR                | 8.3%      | 23.0%     | <0.0001 |           |           |         |
| TVR                |           |           |         |           |           |         |
| MACE               |           |           |         |           |           |         |
| Stent thrombosis   |           |           |         |           |           |         |
| 1-year to 2-year   |           |           |         |           |           |         |
| death              |           |           |         |           |           |         |
| MI                 |           |           |         |           |           |         |
| TLR                | 1.7%      | 0.8%      | 0.17    |           |           |         |
| TVR                |           |           |         |           |           |         |
| MACE               |           |           |         |           |           |         |
| Stent thrombosis   |           |           |         |           |           |         |

BMS, bare metal stent; MI, myocardial infarction; MACE, major adverse cardiac events; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent; TLR, target lesion revascularization; TVR, target vessel revascularization.
At present, small vessel stenting by using either PES or SES seems to be safe and does not increase adverse cardiac events in short- and medium-term follow-up. However, long-term follow-up and larger sample multicenter studies are needed to determine whether DES implantation is safe in patients with small vessel CAD.

Conclusion
In this manuscript, we reviewed the placement of BMS, PES, and SES in small vessels with respect to efficacy and safety. At present, the following general conclusions about small vessel stenting can be made: (1) PES considerably reduce the incidence of angiographic restenosis and TLR as compared to BMS; (2) a trend is observed with regard to better angiographic and clinical outcomes of SES over PES, but there is little and weak information to support this result; and (3) Both PES and SES seem to be safe and don’t increase severe cardiac complications, such as acute and late stent thrombosis.

Even in the DES era, small RVD is still an independent predictor of angiographic and clinical restenosis (Kastrati 2006). However, there are a very limited number of studies focusing on small vessel DES stenting. Therefore, large-sample size, double-blinded, randomized-controlled multicenter trials with long-term follow-up and a clinical primary endpoint are needed to establish the fact that both PES and SES are effective and safe in small vessel coronary disease.

References
Agostoni P, Biondi-Zoccai GG, Gasparini GL, et al. 2005. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J, 26:881–9.
Akiyama T, Moussa I, Reimers B, et al. 1998. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol, 32:1610–8.
Aoki J, Colombo A, Dudek D, et al. 2005a. Persistent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation, 112:3876–83.
Aoki J, Abizaid AC, Serruys PW, et al. 2005b. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol, 46:1670–6.
Aoki J, Abizaid AC, Ong AT, et al. 2005c. Serial assessment of tissue growth inside and outside the stent after implantation of drug-eluting stent in clinical trials. – Does delayed neointimal growth exist? EuroInterv, 1:253–5.
Ardissono D, Cavallini C, Bramucci E, et al. 2004. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA, 292:2727–34.
Axel DI, Kunert W, Goggelmann C, et al. 1997. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 96:636–45.
Bauters C, Hubert E, Prat A, et al. 1998. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol, 32:1291–8.
Betrua A, Masotti M, Serra A, et al. 1999. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol, 34:1498–506.
Briguori C, Sarais C, Pagnotta P, et al. 2002. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol, 40:403–9.
Brophy JM, Belisle P, Joseph L. 2003. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med, 138:777–86.
Carter AJ, Aggarwal M, Kopia GA, et al. 2004. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res, 63:617–24.
Colombo A, Drzewiecki J, Banning A, et al. 2003. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation, 108:788–94.
Dawkins KD, Grube E, Guagliumi G, et al. 2005. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation, 112:3306–13.
Degertekin M, Serruys PW, Foley DP, et al. 2002. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation, 106:1610–3.
de Lezo J MA, Pan M, Romero M, et al. 2005. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol, 45:75A.
Dibra A, Kastrati A, Mehlich J, et al. 2005. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med, 353:663–70.
Farb A, Heller PF, Shroff S, et al. 2001. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation, 104:473–9.
Fischman DL, Leon MB, Baim DS, et al. 1994. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med, 331:496–501.
Giannakakou P, Robey R, Fojo T, et al. 2001. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene, 20:3806–13.
Goy JJ, Stauffer JC, Siegenthaler M, et al. 2005. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXI trial. J Am Coll Cardiol, 45:308–11.
Grube E, Silber S, Hauptmann KE, et al. 2003. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation, 107:38–42.
Guagliumi G, Farb A, Musumeci G, et al. 2003. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation, 107:1340–1.
Hofma SH, van der Giessen WJ, van Dalen BM, et al. 2006. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J, 27:166–70.
Holmes DR, Jr., Leon MB, Moses JW, et al. 2004. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation, 109:634–40.
Hui A, Min WX, Tang J, et al. 1998. Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes. Arthritis Rheum, 41:869–76.
Iakovou I, Schmidt T, Bonizzoni E, et al. 2005. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 293:2126–30.
Joner M, Finn AV, Farb A, et al. 2006. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol, 48:193–202.

Karrillon GJ, Morice MC, Benveniste E, et al. 1996. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation, 94:1519–27.

Kastrati A, Schomig A, Dirschinger J, et al. 2000. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation, 102:2593–8.

Kastrati A, Mehilli J, von Beckerath N, et al. 2005a. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA, 293:165–71.

Kastrati A, Dibra A, Eberle S, et al. 2005b. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA, 294:819–25.

Kastrati A, Dibra A, Mehilli J, et al. 2006. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation, 113:2293–300.

Kiemeneij F, Serruys PW, Macaya C, et al. 2001. Continued benefit of clinical benefit of Benestent-I trial. J Am Coll Cardiol, 37:1598–603.

Koning R, Eltchaninoff H, Commeau P, et al. 2001. Stent placement compared with balloon angioplasty for small coronary arteries: in-hospital and 6-month clinical and angiographic results. Circulation, 104:1604–8.

Lau KW, Ding ZP, Sim LL, et al. 2000. Clinical and angiographic outcome after angiography-guided stent placement in small coronary vessels. Am Heart J, 139:830–9.

Macaya C, Serruys PW, Ruygrok P, et al. 1996. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent-I trial. J Am Coll Cardiol, 27:255–61.

Mak KH, Belli G, Ellis SG, et al. 1996. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol, 27:494–503.

McFadden EP, Stabile E, Regar E, et al. 2004. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 364:1519–21.

Mehilli J, Dibra A, Kastrati A, et al. 2006. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J, 27:260–6.

Moer R, Myer Y, Molstad P, et al. 2001. Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. J Am Coll Cardiol, 38:598–603.

Moreno R, Fernandez C, Hernandez R, et al. 2005. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol, 45:954–9.

Morice MC, Colombo A, Meier B, et al. 2006. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA, 295:895–904.

Moses JW, Leon MB, Popma II, et al. 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 349:1315–23.

Moussa I, Di Mario C, Reimers B, et al. 1997. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol, 29:6–12.

Nebeher JR, Virmani R, Bennett CL, et al. 2006. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol, 47:175–81.

Ong AT, McFadden EP, Regar E, et al. 2005. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol, 45:2088–92.

Park KH, Park SW, Hong MK, et al. 2006. Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions. Catheter Cardiovasc Interv, 67:589–94.

Park SW, Lee CW, Hong MK, et al. 2000. Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J, 21:1785–9.

Popma JJ, Leon MB, Moses JW, et al. 2004. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation, 110:3773–80.

Rodriguez-Granillo GA, Valgimigli M, Garcia-Garcia HM, et al. 2005. One-year clinical outcome after coronary stenting of very small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: a comparison between the RESEARCH and T-SEARCH registries. J Invasive Cardiol, 17:409–12.

Schampaert E, Cohen EA, Schluter M, et al. 2004. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol, 43:1110–15.

Schofer J, Schluter M, Gershlick AH, et al. 2003. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet, 362:1093–9.

Serruys PW, de Jaegere P, Kiemeneij F, et al. 1994. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med, 331:489–95.

Serruys PW, Kay IP, Disco C, et al. 1999. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NETHERlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol, 34:1067–74.

Silber S, Albersson P, Aviles FF, et al. 2005. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J, 26:804–47.

Stone GW, Ellis SG, Cox DA, et al. 2004a. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med, 350:221–31.

Stone GW, Ellis SG, Cox DA, et al. 2004b. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation, 109:1942–7.

Stone GW, Ellis SG, Cannon L, et al. 2005. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA, 294:1215–23.

Tanabe K, Serruys PW, Grube E, et al. 2003. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation, 107:559–64.

Tanimoto S, Daemen J, Tsuchida K, et al. 2006. Two-year clinical outcome after coronary stenting of small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: Insight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv, in press.

Virmani R, Guagliumi G, Farb A, et al. 2004. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation, 109:701–5.

Weisz G, Leon MB, Holmes DR, Jr., et al. 2006. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol, 47:1350–5.

Windecker S, Remondino A, Eberli FR, et al. 2005. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med, 353:653–62.

Wong P, Lau KW, Lim YL, et al. 2000. Stent placement for non-STRESS/BENESTENT lesions: a critical review. Catheter Cardiovasc Interv, 51:223–33.